Happy drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care: Results from the BioCAPTURE network

British Journal of Dermatology

Volumn 171, Issue 5, 2014, Pages 1189-1196

  Van Den Reek, J M P A ^a   Zweegers, J ^a   Kievit, W ^a   Otero, M E ^a   Van Lumig P P M ^a   Driessen, R J B ^a   Ossenkoppele, P M ^b   Njoo, M D ^b   Mommers, J M ^c   Koetsier, M I A ^d   Arnold, W P ^e   Sybrandy Fleuren, B A M ^f   Kuijpers, A L A ^g   Andriessen, M P M ^h   Van De Kerkhof, P C M ^a   Seyger, M M B ^a   De Jong, E M G J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Hospital Group Twente   (Netherlands)

^c ST ANNA HOSPITAL   (Netherlands)

^d GELRE HOSPITALS   (Netherlands)

^e GELDERSE VALLEI HOSPITAL   (Netherlands)

^f SLINGELAND HOSPITAL   (Netherlands)

^g MÁXIMA MEDICAL CENTER   (Netherlands)

^h JEROEN BOSCH HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; USTEKINUMAB; DERMATOLOGICAL AGENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ARTICLE; CLINICAL PRACTICE; COHORT ANALYSIS; DERMATOLOGY LIFE QUALITY INDEX; DRUG DOSE REDUCTION; DRUG SURVIVAL; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROSPECTIVE STUDY; PSORIASIS; QUALITY OF LIFE; SURVIVAL; SURVIVAL RATE; UNSPECIFIED SIDE EFFECT; DRUG SUBSTITUTION; KAPLAN MEIER METHOD; MIDDLE AGED; PATIENT SATISFACTION; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, HUMANIZED; DERMATOLOGIC AGENTS; DRUG SUBSTITUTION; FEMALE; HUMANS; IMMUNOGLOBULIN G; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PATIENT SATISFACTION; PROSPECTIVE STUDIES; PSORIASIS; QUALITY OF LIFE; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME;

EID: 84911428884     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.13087     Document Type: Article

References (39)

1. Horiuchi T, Mitoma H, Harashima S, et al,. Transmembrane TNF-α: structure, function and interaction with anti-TNF agents. Rheumatology 2010; 49: 1215-28.
2. Benson JM, Sachs CW, Treacy G, et al,. Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab. Nat Biotechnol 2011; 29: 615-24.
3. Leonardi C, Strober B, Gottlieb AB, et al,. Long-term safety and efficacy of etanercept in patients with psoriasis: an open-label study. J Drugs Dermatol 2010; 9: 928-37.
4. Moore A, Gordon KB, Kang S, et al,. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. J Am Acad Dermatol 2007; 56: 598-603.
5. Schmitt J, Rosumeck S, Thomaschewski G, et al,. Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. Br J Dermatol 2014; 170: 274-303.
6. Tyring S, Gordon KB, Poulin Y, et al,. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol 2007; 143: 719-26.
7. van de Kerkhof PC, Segaert S, Lahfa M, et al,. Once-weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension. Br J Dermatol 2008; 159: 1177-85.
8. Kimball AB, Papp KA, Wasfi Y, et al,. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. J Eur Acad Dermatol Venereol 2013; 27: 1535-45.
9. Tsai TF, Ho JC, Song M, et al,. Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL). J Dermatol Sci 2011; 63: 154-63.
10. Kumar N, Narang K, Cressey BD, Gottlieb AB,. Long-term safety of ustekinumab for psoriasis. Expert Opin Drug Saf 2013; 12: 757-65.
11. Papp KA, Griffiths CE, Gordon K, et al,. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol 2013; 168: 844-54.
12. Puig L, Lopez A, Vilarrasa E, García I,. Efficacy of biologics in the treatment of moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials with different time points. J Eur Acad Dermatol Venereol 2013 [Epub ahead of print].
13. Pariser DM, Leonardi CL, Gordon K, et al,. Integrated safety analysis: short- and long-term safety profiles of etanercept in patients with psoriasis. J Am Acad Dermatol 2012; 67: 245-56.
14. Igarashi A, Kato T, Kato M, et al,. Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3 clinical trial. J Dermatol 2012; 39: 242-52.
15. Menter A, Tyring SK, Gordon K, et al,. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008; 58: 106-15.
16. Leonardi C, Papp K, Strober B, et al,. The long-term safety of adalimumab treatment in moderate to severe psoriasis: a comprehensive analysis of all adalimumab exposure in all clinical trials. Am J Clin Dermatol 2011; 12: 321-37.
17. Gordon KB, Langley RG, Leonardi C, et al,. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006; 55: 598-606.
18. Asahina A, Nakagawa H, Etoh T, et al,. Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a phase II/III randomized controlled study. J Dermatol 2010; 37: 299-310.
19. Brunasso AM, Puntoni M, Massone C,. Drug survival rates of biologic treatments in patients with psoriasis vulgaris. Br J Dermatol 2012; 166: 447-9.
20. Esposito M, Gisondi P, Cassano N, et al,. Survival rate of anti-TNF-α treatments for psoriasis in routine dermatological practice: a multicentre observational study. Br J Dermatol 2013; 169: 666-72.
21. Gniadecki R, Kragballe K, Dam TN, Skov L,. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. Br J Dermatol 2011; 164: 1091-6.
22. Lopez-Ferrer A, Vilarrasa E, Gich IJ, Puig L,. Adalimumab for the treatment of psoriasis in real life: a retrospective cohort of 119 patients at a single spanish centre. Br J Dermatol 2013; 169: 1141-7.
23. van den Reek JM, van Lümig PP, Driessen RJ, et al,. Determinants of drug survival of etanercept for psoriasis in a long-term daily practice cohort. Br J Dermatol 2013; 170: 415-24.
24. Clemmensen A, Spon M, Skov L, et al,. Responses to ustekinumab in the anti-TNF agent-naive vs. anti-TNF agent-exposed patients with psoriasis vulgaris. J Eur Acad Dermatol Venereol 2011; 25: 1037-40.
25. Umezawa Y, Nobeyama Y, Hayashi M, et al,. Drug survival rates in patients with psoriasis after treatment with biologics. J Dermatol 2013; 40: 1008-13.
26. Finlay AY, Khan GK,. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-16.
27. Finlay AY, Basra MK, Piguet V, Salek MS,. Dermatology Life Quality Index (DLQI): a paradigm shift to patient-centered outcomes. J Invest Dermatol 2012; 132: 2464-5.
28. Hongbo Y, Thomas CL, Harrison MA, et al,. Translating the science of quality of life into practice: what do Dermatology Life Quality Index scores mean? J Invest Dermatol 2005; 125: 659-64.
29. Zweegers J, de Jong JE, Nijsten TE, et al,. Summary of the Dutch S3-guidelines on the treatment of psoriasis 2011. Dermatol Online J 2014; 20: doj-21769
30. Nast A, Boehncke WH, Mrowietz U, et al,. S3-Guidelines on the treatment of psoriasis vulgaris (English version). Update. J Deutsch Dermatol Ges 2012; 10 (Suppl. 2): S1-95.
31. Glintborg B, Østergaard M, Dreyer L, et al,. Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor α therapy: results from the nationwide Danish DANBIO registry. Arthritis Rheum 2011; 63: 382-90.
32. Bissonnette R, Bolduc C, Poulin Y, et al,. Efficacy and safety of adalimumab in patients with plaque psoriasis who have shown an unsatisfactory response to etanercept. J Am Acad Dermatol 2010; 63: 228-34.
33. Cassano N, Galluccio A, De Simone C, et al,. Influence of body mass index, comorbidities and prior systemic therapies on the response of psoriasis to adalimumab: an exploratory analysis from the APHRODITE data. J Biol Regul Homeost Agents 2008; 22: 233-7.
34. Martyn-Simmons CL, Green L, Ash G, et al,. Adalimumab for psoriasis patients who are non-responders to etanercept: open-label prospective evaluation. J Eur Acad Dermatol Venereol 2009; 23: 1394-7.
35. Ortonne JP, Chimenti S, Reich K, et al,. Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVE. J Eur Acad Dermatol Venereol 2011; 25: 1012-20.
36. Papoutsaki M, Chimenti MS, Costanzo A, et al,. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics. J Am Acad Dermatol 2007; 57: 269-75.
37. Van L, Modi SV, Yang DJ, Hsu S,. Sustained efficacy and safety of adalimumab in psoriasis treatment: a retrospective study of 49 patients with and without a history of TNF-α antagonist treatment. Arch Dermatol 2008; 144: 804-6.
38. van Lümig PP, van de Kerkhof PC, Boezeman JB, et al,. Adalimumab therapy for psoriasis in real-world practice: efficacy, safety and results in biologic-naive vs. non-naive patients. J Eur Acad Dermatol Venereol 2013; 27: 593-600.
39. Yamauchi PS, Mau N,. Adalimumab treats psoriasis in patients previously treated with etanercept: a case series. J Am Acad Dermatol 2009; 61: 158-60.